Disease specific therapies in leukodystrophies and leukoencephalopathies
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The leukodystrophies are a heterogeneous, often progressive group of disorders manifesting a wide range of symptoms and complications. Most of these disorders have historically had no etiologic or disease specific therapeutic approaches. Recently, a greater understanding of the pathologic mechanisms associated with leukodystrophies has allowed clinicians and researchers to prioritize treatment strategies and advance research in therapies for specific disorders, some of which are on the verge of pilot or phase I/II clinical trials. This shifts the care of leukodystrophy patients from the management of the complex array of symptoms and sequelae alone to targeted therapeutics. The unmet needs of leukodystrophy patients still remain an overwhelming burden. While the overwhelming consensus is that these disorders collectively are symptomatically treatable, leukodystrophy patients are in need of advanced therapies and if possible, a cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“…gene therapy has shown encouraging results in ALD patients where its use has resulted in polyclonal hematopoietic repopulation, stable transgene expression, and stabilization or reversal of demyelination [9] and is entering phase II/III clinical trials (ClinicalTrials.gov identifier: NCT01896102).”
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280 · cited 1×
“Experiments in the murine model of AGS have demonstrated over-accumulation of endogenous retro elements [24,25] while SAM domain and HD domain-containing protein 1 (SAMHD1) have been shown to be a dominant suppressor of Long Interspersed Element 1 (LINE-1).”
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923 · cited 1×
“Pathogenic mutations appear to result in the aberrant accumulation of RNA: DNA (ribonucleic acid: deoxyribonucleic acid) hybrids and other immunogenic nucleic acid structures within the cell [18–21].”
Self-citationEngelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562 · cited 1×
“X - ALD is one of the most common leukodystrophies and disease-specific management guidelines have recently been published [4].”
Peters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329 · cited 1×
“In patients with cerebral X-ALD, Hematopoietic Stem Cell Transplantation (HSCT) has been shown to improve survival and stabilize or improve cognitive abilities, but only if treatment is initiated during the early stages of cerebral demyelination when the lesion is still relatively small [5–7], highlighting the importa…”
Long-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307 · cited 1×
“Treated children showed decreased brain NAA concentrations, MRI changes suggesting more normal myelination and stabilization of brain atrophy, and evidence for improved clinical status on long-term follow-up [31].”
Miller, W. P., Rothman, S. M., Nascene, D., Kivisto, T., DeFor, T. E., Ziegler, R. S., Eisengart, J., Leiser, K., Raymond, G., Lund, T. C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329235 · Cited by 290 · cited 1×
“Factors associated with favorable treatment outcomes include low pre-transplant Loes radiographic severity score [8], limited degree of neurologic disability and high neuropsychometric measures after HSCT intervention [5,7].”
Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil
Moser, H. W., Raymond, G. V., Lu, S.-E., Muenz, L. R., Moser, A. B., Xu, J., Jones, R. O., Loes, D. J., Melhem, E. R., Dubey, P., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1073 · Cited by 239 · cited 2×
“In boys who have not yet developed cerebral ALD, daily consumption of Lorenzo's Oil, a mixture of oleic and erucic acid, in combination with dietary restriction of very long chain fatty acids, may helpmitigate the risk of developing cerebral demyelination [11].”
Modulation of LINE-1 and Alu/SVA Retrotransposition by Aicardi-Goutières Syndrome-Related SAMHD1
Zhao, K., Du, J., Han, X., Goodier, J. L., Li, P., Zhou, X., Wei, W., Evans, S. L., Li, L., Zhang, W., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.019 · Cited by 194 · cited 1×
“AGS-related mutations compromise the potency of SAMHD1 against LINE-1 retrotransposition [26].”
An autoimmune disease prevented by anti-retroviral drugs
Beck-Engeser, G. B., Eilat, D., & Wabl, M. (2011) · Retrovirology · doi:10.1186/1742-4690-8-91 · Cited by 117 · cited 1×
“Within the murine model of AGS, the use of reverse transcriptase inhibitors presumably targeting production of endogenous retroelements has been studied with promising results [27].”
Head trauma can initiate the onset of adreno-leukodystrophy
Raymond, G. V., Seidman, R., Monteith, T. S., Kolodny, E., Sathe, S., Mahmood, A., & Powers, J. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.11.005 · Cited by 90 · cited 1×
“Step-wise decline may also occur following infection in Pol III-related leukodystrophies [74] or in AGS [22], and after head trauma in X-ALD [76].”
Enzyme, cell and gene‐based therapies for metachromatic leukodystrophy
Sevin, C., Aubourg, P., & Cartier, N. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0540-z · Cited by 88 · cited 1×
“Bone marrow transplantation has been shown to halt demyelination in minimally symptomatic patients with juvenile or adult MLD [60].”
Weber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt645 · Cited by 63
Theda, C., Gibbons, K., DeFor, T. E., Donohue, P. K., Golden, W. C., Kline, A. D., Gulamali-Majid, F., Panny, S. R., Hubbard, W. C., Jones, R. O., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.10.019 · Cited by 56 · cited 1×
“Newborn screening for X-ALD is being implemented in a growing number of US states and is performed through the measurement of 26:0-lyso-PC levels and the ratios of 26:0-lyso-PC to 20L0-lyso-PC [10].”
Aminoacyl-tRNA Synthetases in Biology and Medicine
(2014) · Topics in Current Chemistry · doi:10.1007/978-94-017-8701-7 · Cited by 36
Cited by
Diagnosis, prognosis, and treatment of leukodystrophies
van der Knaap, M. S., Schiffmann, R., Mochel, F., & Wolf, N. I. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30143-7 · Cited by 175
Self-citationGene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91
“Similarly to MLD, HSCT has been shown to be efficacious in Krabbe’s disease but only in patients with later onset of disease or in presymptomatic infants (Krivit et al., 1999b; Helman et al., 2015).”
BackgroundMethodResultRemyelination in the central nervous system
Franklin, R. J. M., Bodini, B., & Goldman, S. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041371 · Cited by 40
Self-citationTreatment of leukodystrophies: Advances and challenges.
Wolf, N. I., van der Knaap, M. S., & Engelen, M. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.03.016 · Cited by 11
Metadata
- Authors
- Helman, G., Van Haren, K., Bonkowsky, J. L., Bernard, G., Pizzino, A., Braverman, N., Suhr, D., Patterson, M. C., Ali Fatemi, S., Leonard, J., van der Knaap, M. S., Back, S. A., Damiani, S., Goldman, S. A., Takanohashi, A., Petryniak, M., Rowitch, D., Messing, A., Wrabetz, L., Schiffmann, R., Eichler, F., Escolar, M. L., & Vanderver, A.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 114
- Issue
- 4
- Pages
- 527-536
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2033542081
- Cited by
- 54
- References
- 17
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.